Agios Pharmaceuticals (AGIO) Soars 5.2%: Is Further Upside Left in the Stock?Zacks Investment Research • 01/04/24
Agios Pharma Surges, And Retakes Its 200-Day Line, On Promising Test Results For Thalassemia DrugInvestors Business Daily • 01/03/24
Agios Pharma's stock soars 19.6% on news of positive results in trial of treatment for rare blood disorderMarket Watch • 01/03/24
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-ThalassemiaGlobeNewsWire • 01/03/24
Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024GlobeNewsWire • 01/02/24
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and ExpositionGlobeNewsWire • 12/10/23
Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic SyndromesGlobeNewsWire • 11/20/23
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and ExpositionGlobeNewsWire • 11/02/23
Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023GlobeNewsWire • 10/19/23
Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023GlobeNewsWire • 08/29/23
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/03/23
Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia VeraGlobeNewsWire • 08/03/23
Wall Street Analysts Think Agios Pharmaceuticals (AGIO) Could Surge 42.06%: Read This Before Placing a BetZacks Investment Research • 07/17/23
Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023GlobeNewsWire • 07/13/23